| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
This compound has no biological target; it is a chemical linker. Its role is to connect an E3 ubiquitin ligase ligand to a target protein ligand within a PROTAC molecule. The PEG2 spacer enhances aqueous solubility and reduces aggregation of the final PROTAC.
|
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
The linker itself possesses no in vitro pharmacological activity. It is a synthetic intermediate. Unconjugated, it does not affect cell viability, enzyme activity, or receptor binding at concentrations typically used (1-100 uM). |
| ln Vivo |
No in vivo activity is reported for the linker alone. In vivo activity would only be observed after incorporation into a complete PROTAC molecule, where the PEG2 linker contributes to favorable pharmacokinetic properties such as increased water solubility and reduced off-target aggregation.
|
| Enzyme Assay |
A non-cell assay is not applicable for the linker alone. However, its solubility can be tested by dissolution in common organic solvents (DMSO, DMF, dichloromethane) and water. The hydrochloride salt enhances crystallinity and stability for synthetic handling.
|
| Cell Assay |
The linker alone is not tested in cell assays. For validation, cells are treated with a PROTAC built from this linker (e.g., 0.1-10 uM, 4-24 h). Target degradation is measured by Western blot. The linker itself should show no biological effect.
|
| Animal Protocol |
No animal studies are performed with the linker alone. Complete PROTAC molecules containing this PEG2 linker are administered to rodents (IV or IP) in efficacy studies. The PEG2 spacer improves the pharmacokinetic profile by reducing hepatic clearance and increasing plasma half-life.
|
| ADME/Pharmacokinetics |
The linker alone has no defined PK. When incorporated into a PROTAC, the PEG2 moiety generally increases aqueous solubility and reduces protein binding, leading to a moderate volume of distribution and extended half-life compared to alkyl linkers.
|
| Toxicity/Toxicokinetics |
The linker alone is non-toxic at the concentrations used for synthesis (e.g., <10 uM). The hydrochloride form is not associated with significant toxicity. PROTACs containing this linker must be evaluated individually for safety. Standard laboratory safety precautions apply.
|
| References |
[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
|
| Additional Infomation |
NH2-PEG2-methyl acetate hydrochloride is a synthetic building block for PROTACs. The free NH2 group forms an amide bond with carboxyl groups on ligands; the methyl ester can be hydrolyzed to a carboxylic acid for alternative conjugation. It is for research use only. Store at 4degC, sealed, away from moisture.
|
| Molecular Formula |
C7H16CLNO4
|
|---|---|
| Molecular Weight |
213.659241676331
|
| Exact Mass |
213.076
|
| CAS # |
208647-73-8
|
| Related CAS # |
NH2-PEG2-methyl acetate;741235-80-3
|
| PubChem CID |
132145168
|
| Appearance |
Light yellow to yellow oil
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
13
|
| Complexity |
118
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(COCCN)OCC(=O)OC.Cl
|
| InChi Key |
LJGPEQCMODSTPF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H15NO4.ClH/c1-10-7(9)6-12-5-4-11-3-2-8;/h2-6,8H2,1H3;1H
|
| Chemical Name |
methyl 2-[2-(2-aminoethoxy)ethoxy]acetate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6803 mL | 23.4017 mL | 46.8033 mL | |
| 5 mM | 0.9361 mL | 4.6803 mL | 9.3607 mL | |
| 10 mM | 0.4680 mL | 2.3402 mL | 4.6803 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
